Business Wire

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced it recently entered into an ...
Business Wire

Melt Pharmaceuticals Submits INDs for MELT‑210 and MELT-400 to FDA

NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first‑in‑class medicines for sedation and analgesia, today announced the filing of two ...
Healio

First patient dosed in Melt’s phase 3 program of needle- and opioid-free cataract sedation

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. MELT-300 is a combination of midazolam and ketamine ...
NextBigFuture

Low Temperature Liquid Metal Could Save 90% of Chemical Industry Energy

A new process instead uses liquid metals, in this case dissolving tin and nickel which gives them unique mobility, enabling them to migrate to the surface of liquid metals and react with input ...